

AngioDynamics To Present at the Adams Harkness Annual Summer Seminar

QUEENSBURY, NY, Jul 25, 2005 (BUSINESS WIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) today announced that its president and CEO, Eamonn P. Hobbs and its CFO, Joseph G. Gerardi will make a formal presentation at the Adams Harkness 25th Annual Summer Seminar on August 2, 2005 at 10:00 AM EDT. The conference will be held from August 2-4, 2005 at the Marriott Long Wharf Hotel in Boston.

Adams Harkness' Annual Summer Seminar is one of the industry's longest-running conferences focusing exclusively on growth markets. The conference will feature 200 public and private companies from the technology, healthcare, and consumer industries along with midyear updates on corporate strategies and other investment issues.

Individuals may listen to a live webcast of the presentation by logging on to the Investor Relations section of AngioDynamics' web site www.AngioDynamics.com a few minutes prior to start time to download any necessary software.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended February 26, 2005, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
Jennifer Chase, (800) 772-6446 x370
www.AngioDynamics.com
or
Investor Relations
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
Bruce Voss, (310) 691-7100
bvoss@lhai.com